Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buprenorphine + naloxone + tenofovir disoproxil fumarate + emtricitabine
- Development stage
- Unknown
- Lead developer
- Duke University
- Modality
- Small Molecules
- Administration
- Oral, Sublingual
01
Overview
This combination therapy refers to the pharmacological components of the Duke University 'PARTNER UP' program, a telemedicine-based harm reduction intervention designed for people who inject drugs (PWID). The program integrates the administration of two fixed-dose combination medications: buprenorphine/naloxone (Suboxone) for medication for opioid use disorder (MOUD) and tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis (PrEP). Buprenorphine acts as a partial mu-opioid agonist to reduce cravings and withdrawal symptoms, while naloxone is included as an abuse deterrent. The PrEP component consists of two nucleoside reverse transcriptase inhibitors (NRTIs) that prevent HIV replication. The program was piloted at syringe services programs in North Carolina to assess the feasibility of using telemedicine for follow-up care in this high-risk population.
- Brand names
- SuboxoneTruvada
- Other names
- PARTNER UPPrEPMOUDtelemedicine MOUD and PrEP
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseKOR (Kappa opioid receptor)DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on buprenorphine + naloxone + tenofovir disoproxil fumarate + emtricitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buprenorphine + naloxone + tenofovir disoproxil fumarate + emtricitabine.